- Home
- CYH vs CSTL Comparison
CYH vs CSTL Comparison
Compare CYH & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYH
- CSTL
- Stock Information
- Founded
- CYH 1985
- CSTL 2007
- Country
- CYH United States
- CSTL United States
- Employees
- CYH N/A
- CSTL N/A
- Industry
- CYH Hospital/Nursing Management
- CSTL Medical Specialities
- Sector
- CYH Health Care
- CSTL Health Care
- Exchange
- CYH Nasdaq
- CSTL Nasdaq
- Market Cap
- CYH 482.7M
- CSTL 456.2M
- IPO Year
- CYH 1991
- CSTL 2019
- Fundamental
- Price
- CYH $3.41
- CSTL $20.30
- Analyst Decision
- CYH Hold
- CSTL Strong Buy
- Analyst Count
- CYH 8
- CSTL 6
- Target Price
- CYH $4.27
- CSTL $37.67
- AVG Volume (30 Days)
- CYH 2.5M
- CSTL 451.0K
- Earning Date
- CYH 07-23-2025
- CSTL 08-04-2025
- Dividend Yield
- CYH N/A
- CSTL N/A
- EPS Growth
- CYH N/A
- CSTL N/A
- EPS
- CYH N/A
- CSTL N/A
- Revenue
- CYH $12,653,000,000.00
- CSTL $347,083,000.00
- Revenue This Year
- CYH N/A
- CSTL N/A
- Revenue Next Year
- CYH $3.49
- CSTL $1.36
- P/E Ratio
- CYH N/A
- CSTL N/A
- Revenue Growth
- CYH 1.05
- CSTL 38.43
- 52 Week Low
- CYH $2.24
- CSTL $15.45
- 52 Week High
- CYH $6.29
- CSTL $35.84
- Technical
- Relative Strength Index (RSI)
- CYH 51.68
- CSTL 66.43
- Support Level
- CYH $3.31
- CSTL $20.00
- Resistance Level
- CYH $3.62
- CSTL $20.63
- Average True Range (ATR)
- CYH 0.16
- CSTL 0.76
- MACD
- CYH 0.01
- CSTL 0.16
- Stochastic Oscillator
- CYH 70.45
- CSTL 88.88
About CYH Community Health Systems Inc.
Community Health Systems Inc is a publicly owned hospital operator in the United States. The company also owns four home health agencies and provides management and consulting services to independent hospitals. The firm derives revenue through a broad range of general and specialized hospital healthcare services and outpatient services.
About CSTL Castle Biosciences Inc.
Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. It also provides DecisionDx-UM, a risk stratification GEP test. The company also offers its products to the skin cancer and gastroenterology markets.